| Today's Big NewsApr 26, 2023 |
|
May 1 - 3, 2023 | Jersey City, NJ
Explore In-Depth Discussions Across 3 Tracks Dedicated to Medical Affairs Professionals. Last chance to register! Don’t miss out,register today.
|
|
| By James Waldron Roche executives have insisted that they haven’t given up on anti-TIGIT checkpoint inhibitors, even as they dodged questions about whether their candidate has flunked yet another phase 3 trial. |
|
|
|
By Nick Paul Taylor Roche no longer sees the magic in MAGE-A4. The Swiss drugmaker signaled a retreat from the TCR T-cell target in its first quarter results by putting a pair of phase 1 solid tumor programs out to pasture. |
By James Waldron GSK’s weighty HIV pipeline just got slightly lighter as the British Big Pharma decided not to progress a once-promising candidate into late-stage trials. |
By Gabrielle Masson Orbital Therapeutics has raised an eye-popping $270 million for its collection of RNA tools and pursuit of next-gen medicines, while also looping in two new execs. |
By Nick Paul Taylor Novartis’ pursuit of the crown jewels of AstraZeneca’s $39 billion Alexion buyout is gathering pace. The latest data show more than 90% of participants in a phase 3 trial experienced the hoped-for improvement after taking the oral factor B inhibitor, boosting the Swiss drugmaker’s prospects of creating a new standard of care. |
By Annalee Armstrong The Supreme Court has for now preserved access to the abortion medication mifepristone—a win for the biopharma world that rallied to support the FDA’s authority to approve drugs. But the women behind the unprecedented letter campaign and amicus brief are not yet breathing a sigh of relief. |
By Max Bayer Flagship Pioneering-founded Evelo is moving on from its lead asset after additional dose cohort data in patients with atopic dermatitis mirrored past failures, with more job cuts on the way. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Angus Liu The FDA has approved another Biogen drug for a neurological disorder. Unlike the controversial go-ahead for Aduhelm, the agency’s neuroscience division didn’t go against its external advisers’ advice this time. |
By Joseph Keenan AmerisourceBergen released its platform focused on cell and gene therapies to speed the exchange of real-time data with the goal of aiding development and ultimately getting novel treatments to patients. |
By Andrea Park Nearly a year-and-a-half after receiving a warning letter from the FDA detailing a list of quality control issues at the Los Angeles-area headquarters of its diabetes business, Medtronic said it has finally resolved all of the regulator’s concerns. |
By Angus Liu Roche’s plans for expanding Tecentriq in early-stage cancers have hit a snag. But the Swiss company’s newly minted pharma chief remains hopeful for an important trial in resectable lung cancer. |
By Healthcare Staff Follow along with the latest news and insights from the Fierce Healthcare team on the fallout from the Supreme Court's Dobbs decision. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we talk about how Pfizer became the first company in Big Pharma history with $100 billion in sales. We also dive into a J&J data leak, Eli Lilly's manufacturing spending plan and more of this week's top headlines. |
|
|---|
|
|
|
July 18-19, 2023 | Jersey City, NJ
Hear the latest industry trends from leaders in the field, and developed with input from our esteemed advisory board, to ensure you have a sound plan for your company, brands, and yourself. Save $500 when you Register Today!
|
|
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| Whitepaper How can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| Whitepaper The preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
| Whitepaper We’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
| Whitepaper How advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
| WhitepaperThis paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
